Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - 20:36:37 19/03/2025 +04 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
-1.00%+4.43%+49.60%+1.42% 84.22B
-1.29%+4.27%+519.00%+32.26% 59.43B
-0.68%+1.14%-17.34%-35.07% 60.48B
-1.60%-7.34%-5.08%+31.05% 50.31B
+0.09%-0.54%+9.26%+165.71% 48.91B
+0.83%+1.36%+58.53%-15.97% 33.17B
-0.64%+0.20%+47.19%+97.87% 25.95B
0.00%-4.65%+2.40%+197.10% 22.78B
+1.10%-1.67%+64.17%+118.01% 16.73B
Average -0.37%+0.47%+63.88%+49.32% 44.66B
Weighted average by Cap. -0.63%+1.40%+95.69%+44.92%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B